Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study.

被引：0

作者：

Ferreira, S. ^{[1
]}

Parra, R. Serafim ^{[2
]}

Sassaki, L. Yukie ^{[3
]}

Parente, J. M. Luz ^{[4
]}

de Mello, M. Kurtz ^{[5
]}

Chebli, L. Andrade ^{[6
]}

Luporini, R. L. ^{[7
]}

Alves Junior, A. J. Tiburcio ^{[8
]}

Nobrega, F. J. Firmino ^{[9
]}

da Silva, B. C. ^{[10
]}

Miranda, E. F. ^{[11
]}

Quaresma, A. Botelho ^{[12
]}

Nicollelli, G. Mattioli ^{[13
]}

Gasparini, R. Galhardi ^{[14
]}

Dutra, R. de Medeiros ^{[3
]}

da Silva, K. da Conceicao ^{[15
]}

Magro, D. Oliveira

Imbrizi, M. R. ^{[16
]}

Nagasako, C. Kibune ^{[17
]}

Feres, O. ^{[18
]}

Troncon, L. E. de Almeida ^{[19
]}

Kotze, P. G. ^{[20
]}

Chebli, J. M. Fonseca ^{[21
]}

机构：

[1] Hosp Clin Ribeirao Preto Med Sch, Med, Ribeirao Preto, Brazil

[2] Hosp Clin Ribeirao Preto Med Sch, Surg & Anat, Ribeirao Preto, SP, Brazil

[3] Sao Paulo State Univ UNESP, Med Sch, Internal Med, Botucatu, Brazil

[4] Univ Fed Piaui, Hlth Sci Ctr, Div Gastroenterol Med Course, Teresina, Brazil

[5] Univ Vale Itajai, Med, Itajai, Brazil

[6] Univ Fed Juiz de Fora, Div Gastroenterol, Med, Juiz De Fora, Brazil

[7] Fed Univ Sao Carlos UFSCar, Med, Sao Carlos, Brazil

[8] PUC Campinas Med Sch, Surg, Campinas, Brazil

[9] Univ Fed Paraiba, Lauro Wanderley Hosp, Gastroenterol, Joao Pessoa, Brazil

[10] Hosp Bahia, Gastroenterol, Salvador, Brazil

[11] Pontificia Univ Catolica Parana PUCPR, Surgey, Curitiba, Brazil

[12] Univ Oeste Santa Catarina UNOESC, Surg, Joacaba, Brazil

[13] Hosp Clin UFPR, Surg, Curitiba, Brazil

[14] Sete Specialized Med Ctr, Marilia, Brazil

[15] Hosp Univ Univ Fed Piaui, Med, Teresina, Brazil

[16] State Univ Campinas UNICAMP, Surg, Campinas, Brazil

[17] State Univ Campinas UNICAMP, Med, Campinas, Brazil

[18] Univ Sao Paulo, Ribeirao Preto Med Sch, Surg & Anat, Ribeirao Preto, Brazil

[19] Univ Sao Paulo, Ribeirao Preto Med Sch, Med, Ribeirao Preto, Brazil

[20] Pontificia Univ Catol Parana PUCPR, Hlth Sci Postgrad Program, Curitiba, Brazil

[21] Univ Fed Juiz de Fora, Div Gastroenterol, Med, Juiz De Fora, Brazil

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0856

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0682

引用

页码：i1335 / i1336

页数：2

共 50 条

[1] BIOLOGIC THERAPY SEQUENCING IN ULCERATIVE COLITIS: A REAL-WORLD OBSERVATIONAL STUDY OF SECOND-LINE THERAPY AFTER VEDOLIZUMAB
Anyanwu, Precious A.
Fernandes, Christopher
Van Anglen, Lucinda J.
Chou, Chiahung
Sanchirico, Marie
Sarles, Harry
Chapman, Casey
Jiang, Jeanne
Fan, Tao
Young, Lisa
Ritter, Timothy
GASTROENTEROLOGY, 2024, 166 (05) : S1147 - S1148
[2] Biologic Therapy Sequencing in Ulcerative Colitis: A Real-World Observational Study of Second-Line Therapy After Vedolizumab
Fernandes, Christopher
Anyanwu, Precious A.
Van Anglen, Lucinda J.
Sarles, Harry
Chapman, Casey
Chou, Chiahung
Jiang, Jeanne
Sanchirico, Marie
Fan, Tao
Young, Lisa
Ritter, Timothy
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S40 - S40
[3] Real-world Positioning and Effectiveness of First- and Second-Line Biological Therapy in Inflammatory Bowel Diseases
Reves, Joana
Torres, Joana
JOURNAL OF CROHNS & COLITIS, 2024, 18 (06): : 787 - 789
[4] Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study
Zagorowicz, Edyta
Cichoz-Lach, Halina
Kopertowska-Majchrzak, Maria
Eder, Piotr
Stawczyk-Eder, Kamila
Talar-Wojnarowska, Renata
Zatorski, Hubert
Solarska-Polchlopek, Anna
Filip, Rafal
Janiak, Maria
Skrobot, Krzysztof
Klopocka, Maria
Liebert, Ariel
Kaczka, Aleksandra
Wojciechowski, Krzysztof
Drygala, Szymon
Michalak, Agata
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (01): : 69 - 77
[5] SAFETY AND EFFECTIVENESS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS: A BRAZILIAN MULTICENTER REAL-WORLD STUDY
Parra, Rogerio S.
Azevedo, Matheus
Chebli, Liliana A.
Zabot, Gilmara P.
Cassol, Ornella S.
Lubini, Marcio
Alves, Antonio, Jr.
Teixeira, Fabio V.
Kotze, Paulo G.
Moraes, Antonio Carlos
Santana, Genoile O.
Froes, Renata
Gasparetti, Newton, Jr.
Feres, Omar
Chebli, Julio
GASTROENTEROLOGY, 2023, 164 (06) : S1004 - S1004
[6] REAL-WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD IN ULCERATIVE COLITIS: A MULTICENTER STUDY
Lieto, Stephen
Scalzo, Nicholas
Huang, Katherine
Khan, Abdul
Xu, Anthony
Pekow, Joel
Rajauria, Palak
Ayoub, Malek
Johnson, Amanda M.
Yarur, Andres
Patel, Anish
Bishu, Shrinivas
Shukla, Richa
Osterman, Mark T.
Paul, Damemarie
Sokol, Uyen
Tharmarajah, Soba
Lawlor, Garrett
Ahmad, Harris
Rubin, David T.
Sands, Bruce E.
Deepak, Parakkal
Ungaro, Ryan C.
GASTROENTEROLOGY, 2024, 166 (05) : S1455 - S1456
[7] REAL-WORLD EFFECTIVENESS AND SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: A MULTICENTER STUDY
Patel, Anish
Johnson, Amanda M.
Berinstein, Jeffrey
Dulaney, David
Fenster, Marc
Ayoub, Malek
Huang, Katherine
Lieto, Stephen
Scalzo, Nicholas
Loftus, Edward V.
Higgins, Peter D.
Chowla, Navreet M.
Reddy, Nikhil
Yarur, Andres
Kuang, Andrew
Shukla, Richa
Sekhri, Shaina
Pekow, Joel
Beniwal-Patel, Poonam
Cohen, Benjamin L.
Gutierrez, Alexandra
Colombel, Jean Frederic
Ciorba, Matthew A.
Bishu, Shrinivas
Ungaro, Ryan C.
Deepak, Parakkal
GASTROENTEROLOGY, 2023, 164 (06) : S1136 - S1137
[8] Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study
Mocci Md Frcp, G.
Costa, F.
Ceccarelli, L.
Savarino, E.
Mucherino, C.
Marzo, M.
Scaldaferri, F.
Napolitano, D.
Pugliese, D.
Gravina, A. G.
Pellegrino, R.
Spagnuolo, R.
Cuomo, A.
Maconi, G.
Bertani, L.
Bodini, G.
Orru, G.
Piergallini, S.
Scarcelli, A.
Capone, P.
Cortellini, F.
Rodino, S.
Vespere, G.
Gaiani, F.
Pagnini, C.
Graziani, G.
Allegretta, L.
Ferronato, A.
Ribaldone, D. G.
Aragona, G.
Forti, G.
Di Fonzo, M.
Iacopini, F.
Pica, R.
Onidi, M. F.
Usai Satta, P.
Elisei, W.
Picchio, M.
Papa, A.
Tursi, A.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1946 - i1946
[9] The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
Ye, Byong Duk
Cheon, Jae Hee
Song, Ki Hwan
Kim, Joo Sung
Kim, Young-Ho
Yoon, Hyuk
Lee, Kang-Moon
Kang, Sang-Bum
Jang, Byung Ik
Park, Jae Jun
Kim, Tae Oh
Lee, Dae-Wook
Foo, Chee Yoong
Shin, Jeong Eun
Park, Dong Il
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
[10] Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
Tursi, Antonio
Mocci, Giammarco
Cingolani, Linda
Savarino, Edoardo
Pica, Roberta
Cocco, Andrea
Zippi, Maddalena
Napolitano, Daniele
Schiavoni, Elisa
Pugliese, Daniela
Scaldaferri, Franco
Costa, Francesco
Marzo, Manuela
Serio, Mariaelena
Scarcelli, Antonella
Bolognini, Laura
Bendia, Emanuele
Maconi, Giovanni
Cannatelli, Rosanna
Piergallini, Simona
Bodini, Giorgia
Calabrese, Francesco
Ferronato, Antonio
Pranzo, Giuseppe
Elisei, Walter
Monterubbianesi, Rita
Faggiani, Roberto
Rodino, Stefano
Sebkova, Ladislava
Grossi, Laurino
Gaiani, Federica
de Angelis, Gianluigi
Lorenzetti, Roberto
Allegretta, Leonardo
Cazzato, Alessia Immacolata
Scorza, Stefano
Della Valle, Nicola
Sacco, Rodolfo
Forti, Giacomo
Colucci, Raffaele
Tonti, Paolo
Neve, Viviana
Rocco, Giulia
Sacchi, Carlotta
Zampaletta, Costantino
Pagnini, Cristiano
Graziani, Maria Giovanna
Di Paolo, Maria Carla
Onidi, Francesca Maria
Satta, Paolo Usai
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (14) : 1649 - 1656

← 1 2 3 4 5 →